Why Bio-Path Holdings Shares Are Surging Higher Today

Bio-Path Holdings Inc BPTH is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 in refractory/relapsed acute myeloid leukemia patients.

“AML patients that fail frontline venetoclax-based therapy have very poor prognosis with a median overall survival of less than three months and a novel treatment modality is urgently needed for such patients," said Peter Nielsen, president and CEO of Bio-Path Holdings.

"Preclinical studies indicate that the BP1002 and decitabine combination is effective against venetoclax-resistant cell lines, suggesting that the BP1002 and decitabine combination therapy may provide benefits to patients who have relapsed from venetoclax-based treatment,” Nielsen added.

Bio-Path Holdings is a clinical and preclinical stage RNAi nanoparticle drug development company focused on developing a portfolio of targeted nucleic acid cancer drugs.

Price Action: Bio-Path Holdings has traded as high as $24.34 and as low as $3.12 over a 52-week period.

At last check Tuesday, the stock was up 22% at $6.93.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDAPeter Nielsenwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!